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Abstract
Introduction: Reduced left ventricular function in patients with severe symptomatic valvular aortic stenosis is associated
with impaired clinical outcome in patients undergoing surgical aortic valve replacement (SAVR). Transcatheter Aortic Valve
Implantation (TAVI) has been shown non-inferior to SAVR in high-risk patients with respect to mortality and may result in
faster left ventricular recovery.
Methods: We investigated clinical outcomes of high-risk patients with severe aortic stenosis undergoing medical treatment
(n = 71) or TAVI (n = 256) stratified by left ventricular ejection fraction (LVEF) in a prospective single center registry.
Results: Twenty-five patients (35%) among the medical cohort were found to have an LVEF#30% (mean 26.764.1%) and 37
patients (14%) among the TAVI patients (mean 25.264.4%). Estimated peri-interventional risk as assessed by logistic
EuroSCORE was significantly higher in patients with severely impaired LVEF as compared to patients with LVEF.30%
(medical/TAVI 38.5613.8%/40.6616.4% versus medical/TAVI 22.5610.8%/22.1612.8%, p ,0.001). In patients undergoing
TAVI, there was no significant difference in the combined endpoint of death, myocardial infarction, major stroke, life-
threatening bleeding, major access-site complications, valvular re-intervention, or renal failure at 30 days between the two
groups (21.0% versus 27.0%, p = 0.40). After TAVI, patients with LVEF#30% experienced a rapid improvement in LVEF (from
2564% to 34610% at discharge, p = 0.002) associated with improved NYHA functional class at 30 days (decrease $1 NYHA
class in 95%). During long-term follow-up no difference in survival was observed in patients undergoing TAVI irrespective of
baseline LVEF (p = 0.29), whereas there was a significantly higher mortality in medically treated patients with severely
reduced LVEF (log rank p= 0.001).
Conclusion: TAVI in patients with severely reduced left ventricular function may be performed safely and is associated with
rapid recovery of systolic left ventricular function and heart failure symptoms.
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Introduction
Reduced left ventricular ejection fraction (LVEF) among
patients with severe aortic stenosis importantly impacts prognosis
in patients treated conservatively, and increases peri-operative risk
in patients undergoing surgical aortic valve replacement (SAVR)
[1–4]. Although mechanical relief of aortic outflow obstruction as
accomplished by SAVR has been shown to compensate for the
increased peri-operative risk in patients with decreased LVEF [5],
severely impaired LVEF remains one of the principal reasons to
defer SAVR [6]. Moreover, recovery of LVEF in response to
SAVR remains variable and difficult to predict. Transcatheter
Aortic Valve Implantation (TAVI) is a less invasive procedure,
which is predominantly performed among patients previously
managed by medical treatment. In patients not considered suitable
candidates for SAVR, TAVI has been shown to reduce mortality
and rehospitalization compared with a conservative strategy [7].
In addition, it has been suggested that TAVI is associated with
favorable effects on LVEF recovery [8]. The safety and efficacy of
TAVI in patients with reduced LVEF (#30%) vis-a`-vis a
conservative strategy has not been resolved. Therefore, we
investigated clinical outcomes of high-risk patients with severe
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aortic stenosis undergoing medical treatment or TAVI stratified by
LVEF in a prospective single-center registry.
Methods
Patient Population
High-risk patients with symptomatic, severe aortic stenosis
deemed at increased surgical risk have been consecutively included
in a prospective single center registry initiated in July 2007.
Inclusion criteria involved (1) symptomatic, severe aortic stenosis
with an echocardiographic mean gradient .40 mmHg or a
calculated aortic valve area ,1 cm2; (2) age $80 years in the
presence of a logistic EuroSCORE .15%. Patients ,80 years of
age were eligible if at least one of the following comorbid
conditions was present: previous cardiac surgery, chronic obstruc-
tive pulmonary disease (forced expiratory volume during one
second ,1.0), severe pulmonary hypertension ($60 mmHg),
porcelain aorta, history of radiation therapy to the mediastinum,
or frailty (BMI ,18 kg/m2). Patients with severe aortic regurgi-
tation due to degenerated aortic valve prosthesis were excluded.
Ethics Statement
The study complies with the Declaration of Helsinki and was
approved by the Ethics Committee of the University of Bern,
Switzerland (www.kek-bern.ch). All subjects gave informed written
consent.
Evaluation and Treatment
After a comprehensive evaluation according to a standardized
protocol including left and right heart catheterization, aortogra-
phy, transthoracic (TTE) and transesophageal echocardiography
(TEE), and CT angiography of the chest, abdomen and pelvis an
interdisciplinary team of interventional cardiologists and cardiac
surgeons reviewed the cases and formed a consensus on treatment
allocation to medical treatment (1), SAVR (2) or TAVI (3) based
on risk assessment, anatomical considerations and patient
preference [9]. For the purpose of this analysis, we focused on
patients allocated to medical treatment or TAVI. Allocation to
medical treatment resulted from patient’s refusal to undergo either
SAVR or TAVI despite the recommendation for an intervention
put forward by the heart team, comorbidities with poor prognosis,
anatomical or technical reasons not allowing for a transcatheter
approach in patients refusing to undergo SAVR, and exceedingly
high estimated risk for intervention. Reasons for TAVI included
refusal of SAVR, advanced age (.80 years) in the setting of a high
surgical risk, or severe comorbidities. Patients with cross-over from
medical treatment or TAVI to SAVR or from medical treatment
to TAVI during the time of follow-up were excluded. Medical
treatment encompassed percutaneous coronary intervention in
case of significant coronary artery disease with limiting angina, as
well as optimal medical treatment for comorbidities such as
congestive heart failure, atrial fibrillation, and hypertension, and
was not necessarily associated with an equally conservative
strategy for treatment of non-cardiac disease manifestations.
Conservative treatment did however not include balloon aortic
valvuloplasty. Also, it was not used as a bridge to TAVI.
Latter was performed through a tranfemoral, transapical, or
transsubclavian approach according to anatomical characteristics
using either the Medtronic CoreValve Revalving system or the
Edwards Sapien valve as previously described [10].
Data collection
Patients treated medically were included into this registry at the
time of the in-hospital evaluation for a potential intervention,
whereas the date of the intervention was considered the time of
inclusion among patients undergoing TAVI. Follow-up was
performed regularly at 1, 6, and 12 months during a clinic visit
or by means of a standardized telephone interview. Furthermore,
all patients were contacted within two months of data freezing for
the purpose of the present analysis. Hospital records and
municipal civil registries were consulted to ascertain vital status.
Medical records, discharge letters, and documentations of
hospitalizations were systematically collected and all suspected
events were adjudicated by an unblinded clinical event committee
consisting of cardiac surgeons and interventional cardiologists.
Definitions
Assessment of left ventricular ejection fraction at baseline was
based on measurements from TTE using planimetry. All endpoint
definitions were in accordance with the criteria suggested by the
Valve Academic Research Consortium [11]. The definition of
cardiovascular death involved any death due to a proximate
cardiac cause or a death of unknown cause, as well as all
procedure-related deaths and death caused by non-coronary
vascular conditions such as cerebrovascular disease, pulmonary
embolism, or other vascular disease. Peri-procedural myocardial
infarction was determined as new ischemic symptoms or signs in
the presence of elevated cardiac biomarkers (two or more post-
procedure samples that were .6–8 hours apart with a 20%
increase in the second sample and a peak value exceeding 10x the
99th percentile upper reference limit (URL), or a peak value
exceeding 5x the 99th percentile URL with new pathological Q
waves in at least two contiguous leads) within 72 hours after the
index procedure. Major stroke encompassed a rapid onset of focal
or global neurological deficit of $24 hours duration necessitating
therapeutic intervention, or documentation of a new intracranial
defect using MRI or CT-scan. The modified RIFLE (Risk, Injury,
Failure, Loss, End-stage kidney disease) classification was used for
the definition of kidney injury which was based upon changes in
serum creatinine up to 72 hours after the procedure. Stage 1 was
determined as an increase of serum creatinine to 150–200% (or an
increase of $26.4 mmol/l), stage 2 required an increase of the
baseline creatinine to 200–300%, and stage 3 was considered in
case of an increase in creatinine of $300% with an acute increase
of at least 44 mmol/l.
Statistical Analysis
All analyses were performed using SPSS Statistics Version 17.0.
Continuous variables are presented as mean 6 standard deviation
(SD) and were compared by means of a two-sided students T-test.
Categorical data are expressed as frequency (percentages), and
were compared using the chi-square and Fishers exact tests.
Survival was estimated using the Kaplan Meier method. We
performed an univariate analysis and included in addition to age
and gender all variables with a p,0.1 into a cox multivariate
regression model to adjust for potential confounders.
Results
Baseline Characteristics
Among 452 patients with severe aortic stenosis at increased
surgical risk, 10 patients died before treatment allocation, and 107
patients underwent SAVR leaving 335 patients allocated to
medical treatment or TAVI as basis of the present study. After
exclusion of two patients with cross-over from medical treatment
to SAVR, one patient with cross-over from TAVI to SAVR, and
five patients with cross-over from medical treatment to TAVI, 71
patients treated medically and 256 patients treated by TAVI
TAVI in Reduced LVEF
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remained for the purpose of the present analysis. The patient
population was divided into four groups according to treatment
strategy (medical treatment versus TAVI) and left ventricular
ejection fraction (LVEF#30% versus LVEF.30%). Severely
impaired LVEF (#30%) was observed in 25 (35%) patients
treated medically (M30-), whereas 46 (65%) patients treated
medically had normal or only moderately reduced LVEF (M30+).
A total of 37 (14%) TAVI patients had severely diminished LVEF
(T30-), whereas 219 (86%) TAVI patients showed normal or
moderately reduced LVEF (T30+) (Figure 1). Baseline character-
istics of the overall patient population undergoing medical
treatment or TAVI stratified by ventricular function are
summarized in Tables 1 and 2. The estimated peri-procedural
risk was higher in the M30- group as compared to the M30+
group (logistic EuroSCORE 38.5613.8% versus 22.5610.8,
p,0.001). Aside from differences in LVEF, other baseline
characteristics including age, gender, body mass index, prevalence
of diabetes or arterial hypertension, history of prior myocardial
infarction or stroke, previous coronary artery bypass grafting, and
prevalence of atrial fibrillation were well balanced among
medically treated patients. In contrast, within the TAVI cohort,
patients of the T30- group substantially differed from patients of
the T30+ group not only with respect to risk scores (e.g. logistic
EuroSCORE 40.6616.4% versus 22.1612.8, p,0.001), but also
with regard to baseline characteristics such as male gender (59.5%
versus 41.1%, p= 0.05), previous percutaneous coronary inter-
vention (32.4% versus 16.0%, p= 0.02), and NYHA functional
class (3.060.6 versus 2.660.8, p = 0.001) (Table 1).
Mean LVEF amounted to 56.269.7% (M30+) and 26.764.1%
(M30-) in patients assigned to a medical strategy, and to
55.6610.0% (T30+) and 25.264.4% (T30-) in patients undergo-
ing TAVI. While mean gradients were lower in patients with
LVEF#30% among TAVI patients (32.5615.8 mmHg for T30-
versus 45.0614.2 mmHg for T30+, p,0.001), the numerical
difference in the medical cohort fell short of statistical significance
(35.0621.2 mmHg for M30- versus 44.9615.5 mmHg for M30+,
p = 0.07). Among T30- the prevalence of patients with a mean
gradient #30 mmHg amounted to 45.9%. Furthermore, LVEF
#30% in patients undergoing TAVI went along with a higher rate
of severe pulmonary hypertension (62.4615.2 mmHg for T30-
versus 51.1616.6 mmHg for T30+, p = 0.006). In contrast,
patients with LVEF#30% in the medical cohort had a higher
prevalence of triple vessel coronary artery disease (52.0% for M30-
versus 26.1% for M30+, p = 0.03) (Table 2).
Short-term Clinical Outcomes
Peri-procedural characteristics and short-term clinical outcome
of patients undergoing TAVI are summarized in Tables 3 and 4.
All-cause mortality at 30 days amounted to 6.8% and 5.4% among
patients of the T30+ and T30- group (p= 1.0), respectively. There
were no differences between patients of group T30+ and T30-
with regard to peri-procedural myocardial infarction (0% versus
2.7%, p= 0.15), major stroke (3.7% versus 5.4%, p= 0.64), access
related complications, bleeding and renal failure. Two patients of
the group T30- required valvular reinterventions, whereas no
valvular reinterventions were performed among patients of the
group T30+ (5.4% for T30- versus 0% for T30+, p = 0.02). Both
patients underwent post-dilatation 13 days and 14 days after
TAVI, respectively, due to severe aortic regurgitation. There was
no significant difference in the incidence of the Valve Academic
Research Consortium (VARC) combined safety end point [11]
between the two groups (21.0% for T30+ versus 27.0% for T30-,
p = 0.40) (Figure 2). Aortic regurgitation .grade 2+ as assessed by
transthoracic echocardiography before discharge was found in
Figure 1. Patient flow according to CONSORT statement.
doi:10.1371/journal.pone.0027556.g001
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26.6% of patients with T.30% versus 36.1% in patients T#30%
(p= 0.31).
Exercise intolerance as assessed by NYHA functional class was
documented at 30 days and is illustrated in Figure 3. Whereas
patients under medical treatment reported an increase in shortness
of breath at 30 days (increase $1 NYHA class in 30.8% of M30-
and 19.3% of M30+), TAVI patients consistently noted an
improvement in exercise tolerance that seemed to be particularly
pronounced among patients of the T30- group (decrease $1
NYHA class in 95% of T30- and 77.3% of T30+).
Long-term Follow-Up
Crude and adjusted long-term survival of patients undergoing
TAVI and medical treatment as a function of LVEF is shown in
Figure 4. Patients undergoing TAVI experienced a favorable long-
term course compared with patients under medical treatment.
Table 1. Baseline Clinical Characteristics.
Medical Treatment Transcatheter Aortic Valve Implantation
LVEF .30%
N=46
LVEF #30%
N=25 P-value
LVEF .30%
N=219
LVEF #30%
N=37 P-value
Age (years) 83.666.2 82.465.5 0.41 82.366.2 81.166.4 0.28
Females n/% 21/45.7 9/26.0 0.46 129/58.9 15/40.5 0.05
BMI (kg/m2) 24.764.0 23.862.8 0.33 26.064.7 25.265.6 0.35
Cardiac Risk Factors
Hypertension n/% 33/71.7 15/60.0% 0.43 172/78.5 28/75.7 0.67
Current smoker n/% 6/13.0% 0 0.08 34/15.5 7/18.9 0.63
Diabetes mellitus n/% 7/15.2 9/36.0% 0.07 49/22.4 13/35.1 0.10
Positive family history n/% 6/13.0 6/24.0 0.32 44/20.1 5/13.5 0.50
Hypercholesterolemia n/% 15/32.6 15/60.0 0.04 135/61.6 19/51.4 0.28
Past Medical History
Prior MI* n/% 10/21.7 9/36.0 0.26 35/16.0 12/32.4 0.02
Prior PCI{ n/% 6/13.0 14/16.0 0.73 48/21.9 10/27.0 0.53
CABG{ n/% 8/17.4 8/32.0 0.23 44/20.1 10/27.0 0.38
Previous stroke n/% 8/17.4 4/16.0 1.0 17/7.8 6/16.2 0.12
PVD1 n/% 9/19.6 7/28.0 0.55 52/23.7 12/32.4 0.30
Symptoms
NYHA || functional class 2.660.7 2.860.8 0.35 2.660.8 3.060.6 0.001
Angina n/% 19/41.3 7/28.0 0.31 65/29.7 10/27.0 0.85
Syncope n/% 10/21.7 3/12.0 0.36 20/9.1 4/10.8 0.76
Cardiac Rhythm
Atrial fibrillation n/% 10/21.7 9/36.0 0.26 56/25.6 10/27.0 0.84
Prior pacemaker n/% 3/6.5 1/4.0 1.0 23/10.5 3/8.1 1.0
Risk Assessment
Log. EuroSCOREa (%) 22.5610.8 38.5613.8 ,0.001 22.1612.8 40.6616.4 ,0.001
Lin. EuroSCOREa (%) 10.561.9 12.561.8 ,0.001 10.362.2 13.162.3 ,0.001
STS scoreu (%) 5.563.2 8.764.6 0.001 6.265.0 7.964.9 0.05
Medical Treatment
Acetylsalicylic acid n/% 27/58.7 9/36.0 0.09 133/60.7 22/59.5 1.0
Clopidogrel n/% 8/17.4 2/8.0 0.48 37/16.9 10/27.0 0.17
Oral anticoagulation n/% 8717.4 12/48.0 0.01 61/27.9 12/32.4 0.56
Diuretic n/% 37/80.4 24/96.0 0.09 144/65.8 29/78.4 0.18
Betablocker n/% 20/43.5 9/36.0 0.62 110/50.2 23/62.2 0.21
ACE-Inhibitor/ARB n/% 21/45.7 8/32.0 0.32 94/42.9 23/62.2 0.03
Ca Channel blocker n/% 5/10.9 0 0.15 29/13.2 0 0.01
Statin (%) 15/32.6 10/40.0 0.61 106/48.4 17/45.9 0.86
*MI = Myocardial Infarction, {PCI = percutaneous coronary intervention,
{CABG = Coroanry Artery Bypass Graft,
1PVD = Peripheral Vascular Disease, || NYHA = New York Heart Association (mean6standard deviation),
a EuroSCORE = European System for Cardiac Operative Risk Evaluation,
uSTS = Society of Thoracic Surgeons.
doi:10.1371/journal.pone.0027556.t001
TAVI in Reduced LVEF
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27556
There was no difference in survival between patients of the T30-
and T30+ group during long-term follow-up in a crude analysis, as
well as after adjustment for age, gender, NYHA functional class,
peripheral vascular disease, prior stroke, atrial fibrillation, and
logistic EuroSCORE (HR 0.97, 95% CI 0.42-2.25; p = 0.94).
Conversely, patients of the M30- group had a significantly higher
mortality exceeding 80% at one year as compared with patients of
the M30+ group (p = 0.001). This difference was maintained after
adjustment for age, gender, and logistic EuroSCORE (HR 2.30,
95% CI 1.06-4.96; p = 0.04).
Echocardiographic follow-up was available in 93% of patients at
discharge and in 79% at a mean follow-up of 1446130 days. No
echocardiographic follow-up was performed in patients allocated
to medical treatment. Patients of the T30- group experienced
Table 2. Imaging Characteristics.
Medical Treatment Transcatheter Aortic Valve Implantation
LVEF .30%
N=48
LVEF #30%
N=23 P-value
LVEF .30%
N=219
LVEF #30%
N=37 P-value
Echocardiography
LVEF (%) 56.269.7 26.764.1 ,0.001 55.6610.0 25.264.4 ,0.001
Mean gradient (mmHg) 44.9615.5 35.0621.2 0.07 45.9616.8 35.2615.9 0.003
AVA (cm2) 0.760.3 0.660.2 0.04 0.760.2 0.660.2 0.54
Cardiac Catheterization
Coronary artery disease 29/63.0 15/60.0 0.80 142/64.8 25/67.6 0.85
Single-vessel CAD* 9/19.6 0 0.03 49/22.4 5/13.5 0.24
Double-vessel CAD* 8/17.4 2/8.0 0.03 27/12.3 3/8.1 0.24
Triple-vessel CAD* 12/26.1 13/52.0 0.03 66/30.1 17/45.9 0.24
Mean gradient (mmHg) 40.8616.5 31.1614.7 0.08 45.0614.2 32.5615.8 ,0.001
AVA{ (cm2) 0.660.2 0.760.3 0.27 0.560.2 0.660.2 0.75
PA{ syst. pressure (mmHg) 56.4620.6 59.5616.5 0.63 52.1616.6 62.4615.2 0.002
PA{ syst. pressure $ 60 mmHg 10/21.7 7/28.0 0.57 45/20.5 16/43.2 0.006
*CAD = Coronary Artery Disease,
{AVA = Aortic Valve Area,
{PA = Pulmonary Artery.
doi:10.1371/journal.pone.0027556.t002
Figure 2. Short-term clinical outcome as assessed by the Valve Academic research Consortium Combined Safety Endpoint at 30
days in patients undergoing TAVI stratified by LVEF.30% or #30%.
doi:10.1371/journal.pone.0027556.g002
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recovery of LVEF from baseline to discharge (from 2564% to
34610%, p= 0.002) that continued to increase during mid-term
follow-up (41613%) (Figure 5).
Discussion
The main findings of the study are as follows.
1. Severely diminished left ventricular function among patients
with severe aortic stenosis treated medically has an important
impact on clinical outcome with dismal prognosis.
2. TAVI in patients with severely impaired left ventricular
function may be performed safely and may not be associated
with an increased peri-procedural risk.
3. Patients with severely diminished LVEF undergoing TAVI
demonstrate a rapid improvement in LV function and may
have a similar prognosis as compared to patients with normal
or moderately reduced LVEF.
4. Among patients with severely diminished LVEF, TAVI
disproportionally improves NYHA functional class as com-
Table 3. Procedural Characteristics.
Medical Treatment Transcatheter Aortic Valve Implantation
LVEF .30%
N=48
LVEF #30%
N=23 P-value
LVEF .30%
N=219
LVEF #30%
N=37 P-value
Aortic Valve Implantation
Transfemoral MCV*n/% na na na 137/62.6 23/62.2 0.86
Transsubclavian MCV*n/% na na na 4/1.8 0 0.86
Transfemoral ES{ n/% na na na 31/14.2 6/16.2 0.86
Transapical ES{ n/% na na na 47/21.5 8/21.6 0.86
Revascularization
Concomitant PCI{ n/% 7/15.2% 3/12.0% 1.0 23/15.5 3/8.1 0.32
Staged PCI{ n/% na na na 21/9.6 2/5.4 0.55
Hospitalization Duration 4.663.7 4.463.7 0.84 10.765.4 12.369.2 0.13
*MCV = Medtronic CoreValve biosprosthesis,
{ES = Edwards Sapien bioprosthesis,
{PCI = Percutaneous Coronary Intervention.
doi:10.1371/journal.pone.0027556.t003
Table 4. Outcome at 30 Days According to Systolic Left-Ventricular Function.
Transcatheter Aortic Valve Implantation
LVEF .30%
N=219
LVEF #30%
N=37 P-value
All Cause Mortality n/% 15/6.8 2/5.4 1.0
Cardiovascular mortality n/% 10/4.6 2/5.4 0.69
Myocardial Infarction n/% 0 1/2.7 0.15
Major Stroke n/% 8/3.7 2/5.4 0.64
Access related complications n/%
Major n/% 13/5.9 3/8.1 0.71
Minor n/% 19/8.7 4/10.8 0.76
Valvular Reintervention n/% 0 2/5.4 0.02
Bleeding n/%
Life-threatening n/% 25/11.4 4/10.8 1.0
Major n/% 68/31.1 10/27.0 0.70
Renal complications n/%
RIFLE* Stage 1 n/% 27/12.3 5/13.5 0.58
RIFLE* Stage 2 n/% 2/0.90 0 0.58
RIFLE* Stage 3 n/% 9/4.1 0 0.58
Pacemaker Implantation n/% 48/21.9 12/32.4 0.21
VARC{-Combined Safety End Point n/% 46/21.0 10/27.0 0.40
*RIFLE = Risk, Injury, Failure, Loss, End-stage kidney disease,
{VARC = Valve Academic Research Consortium.
doi:10.1371/journal.pone.0027556.t004
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pared with patients with normal or moderately reduced
LVEF.
The observational data of the present single center experience
demonstrate the favorable impact of TAVI on recovery of LVEF
and long-term clinical outcome as compared with medical
treatment. Moreover, the risk of peri-procedural complications
in patients with severely impaired LVEF appears to be comparable
to patients with normal or mildly reduced LVEF.
There are several limitations to be considered. First, the
observational, non-randomized nature of the present analysis is
susceptible to a selection bias attributable to the primary allocation
of the selected treatment strategy. The decision whether to
perform TAVI or medical treatment in patients with severely
impaired LVEF was driven by the decision of the interdisciplinary
heart team, by the feasibility based on anatomic and technical
features, and by the final decision of the patient. Second, the
threshold values for categorization of the overall patient cohort
according to LVEF, although arbitrary, were based on previous
clinical studies of patients undergoing SAVR indicating an
association of impaired LVEF with adverse clinical outcome [1–
5]. At last, we might have been unaware of unknown confounding
factors influencing clinical outcome.
Our data highlight the dismal prognosis of patients with severe,
symptomatic aortic stenosis undergoing medical treatment. The
overall estimated rate of mortality after one year amounted to
55% and is in line with the results of the medical group of the
PARTNER B cohort (Placement of AoRtic TraNscathetER
Valve) trial [7]. In our series, stratification according to LVEF
demonstrates comparable baseline characteristics but an excessive
risk of mortality among patients with severely reduced LVEF.
The assessment of peri-procedural complications in the
TAVI cohort using the VARC criteria revealed no differences
between the two groups stratified according to LVEF. In
particular, we observed no differences with regard to all-cause
mortality, incidence of peri-procedural myocardial infarction
or major stroke. The most frequently encountered peri-
procedural complications were bleeding events and vascular
complications, which occurred with similar frequency in both
groups. A higher rate of repeat valvular interventions among
patients of the T30- group may be due to chance but needs
further investigation.
Figure 3. Changes in NYHA Functional Class at 30 days in patients undergoing medical treatment (A) or transcatheter aortic valve
implantation (B) according to LVEF .30% or #30%.
doi:10.1371/journal.pone.0027556.g003
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The overall incidence of adverse events was comparable with
previous reports of patients undergoing TAVI [12–14] and
suggests that TAVI in patients with severely reduced left
ventricular function is not associated with an increased peri-
operative risk. This finding contrasts with data from the surgical
literature showing an increased risk of adverse events of patients
with reduced LVEF [1–5]. For instance, Sharony et al reported a
30-day mortality of 9.6% among patients with LVEF#40% in a
series of 260 patients [3]. Several factors might explain the
negligible role of a diminished LVEF during the peri-procedural
phase of TAVI: the strategy of a pure percutaneous approach
using local anesthesia and mild conscious sedation reduces the risk
of unfavorable hemodynamics during the intervention and the
need of vasoactive drugs. Positioning of the stiff wire in the left
ventricle and the deployment of the bioprosthesis is considered to
be easier in patients with an enlarged ventricle with low output
Figure 4. Survival in patients undergoing medical treatment or TAVI as a function of LVEF.
doi:10.1371/journal.pone.0027556.g004
Figure 5. LVEF on admission, improvement during the in-hospital phase, and after a mean follow-up duration of 144±130 days.
doi:10.1371/journal.pone.0027556.g005
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compared with patients with a small, hypertrophic and hypercon-
tractile ventricle. Furthermore, TAVI provides the possibility of
valve implantation without cardiac arrest and its sequelae like the
need for prolonged ventilation, the risk of renal failure, infection
and neurologic complications [15].
Our data show, that the combination of severe aortic stenosis
and severely reduced left ventricular function is associated with a
dismal prognosis if treated conservatively. In our cohort, more
than half of the patients died within six months of evaluation for
potential intervention and almost 80% died within one year. The
present findings therefore suggest that severely impaired left
ventricular function should not serve as a reason to deny
transcatheter aortic valve implantation. The favorable peri-
procedural outcome was accompanied by a rapid recovery in
LVEF already during the in-hospital phase and eventually
translated into favorable long-term survival comparable to patients
with normal or moderately reduced LVEF. Of note, the mean
aortic transvalvular gradient in patients with LVEF#30 amounted
to 35616 mmHg indicating that low-flow, low-gradient aortic
stenosis was encountered relatively infrequently and a majority of
patients may have maintained some contractile function. Since we
did not routinely perform dobutamine stress echocardiography the
issue whether contractile reserve plays an important role with
respect to prognosis remains unanswered. Nevertheless, patients
with LVEF#30% assigned to medical treatment exhibited similar
transvalvular gradients (35621 mmHg) and were found to have a
considerably higher mortality rate as compared to medically
treated patients with LVEF.30%.
Among patients with severely impaired LVEF symptom status
as assessed by NYHA functional class improved disproportionally
along with a rapid recovery in systolic left ventricular function.
These findings suggest that patients with severely reduced LVEF
may substantially benefit from TAVI.
Conclusions
TAVI in patients with severely reduced left ventricular function
may be performed safely and is associated with rapid recovery of
systolic left ventricular function and heart failure symptoms.
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